These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 10579464

  • 1. A selective dopamine D4 receptor antagonist, NRA0160: a preclinical neuropharmacological profile.
    Okuyama S, Kawashima N, Chaki S, Yoshikawa R, Funakoshi T, Ogawa SI, Suzuki Y, Ikeda Y, Kumagai T, Nakazato A, Nagamine M, Tomisawa K.
    Life Sci; 1999; 65(20):2109-25. PubMed ID: 10579464
    [Abstract] [Full Text] [Related]

  • 2. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.
    Okuyama S, Chaki S, Kawashima N, Suzuki Y, Ogawa S, Kumagai T, Nakazato A, Nagamine M, Yamaguchi K, Tomisawa K.
    Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395
    [Abstract] [Full Text] [Related]

  • 3. Effects of NRA0045, a novel potent antagonist at dopamine D4, 5-HT2A, and alpha1 adrenaline receptors, and NRA0160, a selective D4 receptor antagonist, on phencyclidine-induced behavior and glutamate release in rats.
    Abekawa T, Honda M, Ito K, Koyama T.
    Psychopharmacology (Berl); 2003 Sep; 169(3-4):247-56. PubMed ID: 12898123
    [Abstract] [Full Text] [Related]

  • 4. In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl] pyrrolidin-3-yl]thiazole (NRA0045).
    Okuyama S, Chaki S, Yoshikawa R, Suzuki Y, Ogawa S, Imagawa Y, Kawashima N, Ikeda Y, Kumagai T, Nakazato A, Nagamine M, Tomisawa K.
    J Pharmacol Exp Ther; 1997 Jul; 282(1):56-63. PubMed ID: 9223539
    [Abstract] [Full Text] [Related]

  • 5. In vitro and in vivo pharmacological profile of 5-[2-[4-(6-fluoro-1H-indole-3-yl)piperidin-1-yl]ethyl]-4-(4-fluorophenyl)thiazole-2-carboxylic acid amide (NRA0562), a novel and putative atypical antipsychotic.
    Funakoshi T, Chaki S, Kawashima N, Suzuki Y, Yoshikawa R, Kumagai T, Nakazato A, Kameo K, Goto M, Okuyama S.
    Life Sci; 2002 Aug 09; 71(12):1371-84. PubMed ID: 12127158
    [Abstract] [Full Text] [Related]

  • 6. Effects of selective dopamine D4 receptor blockers, NRA0160 and L-745,870, on A9 and A10 dopamine neurons in rats.
    Kawashima N, Okuyama S, Omura T, Chaki S, Tomisawa K.
    Life Sci; 1999 Aug 09; 65(24):2561-71. PubMed ID: 10619364
    [Abstract] [Full Text] [Related]

  • 7. In vitro and in vivo pharmacological profile of 4-(4-fluorobenzylidene)-1-[2-[5-(4-fluorophenyl)-1H-pyrazol-4-yl] ethyl] piperidine (NRA0161).
    Suzuki Y, Funakoshi T, Chaki S, Kawashima N, Ogawa S, Kumagai T, Nakazato A, Komurasaki T, Okuyama S.
    Life Sci; 2002 Oct 18; 71(22):2603-15. PubMed ID: 12354579
    [Abstract] [Full Text] [Related]

  • 8. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
    Park WK, Jeong D, Cho H, Lee SJ, Cha MY, Pae AN, Choi KI, Koh HY, Kong JY.
    Pharmacol Biochem Behav; 2005 Oct 18; 82(2):361-72. PubMed ID: 16216322
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.
    Leysen JE, Janssen PM, Megens AA, Schotte A.
    J Clin Psychiatry; 1994 May 18; 55 Suppl():5-12. PubMed ID: 7520908
    [Abstract] [Full Text] [Related]

  • 11. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.
    Depoortère R, Bardin L, Auclair AL, Kleven MS, Prinssen E, Colpaert F, Vacher B, Newman-Tancredi A.
    Br J Pharmacol; 2007 May 18; 151(2):253-65. PubMed ID: 17375086
    [Abstract] [Full Text] [Related]

  • 12. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties.
    Oka M, Noda Y, Ochi Y, Furukawa K, Une T, Kurumiya S, Hino K, Karasawa T.
    J Pharmacol Exp Ther; 1993 Jan 18; 264(1):158-65. PubMed ID: 8093723
    [Abstract] [Full Text] [Related]

  • 13. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests.
    Bristow LJ, Collinson N, Cook GP, Curtis N, Freedman SB, Kulagowski JJ, Leeson PD, Patel S, Ragan CI, Ridgill M, Saywell KL, Tricklebank MD.
    J Pharmacol Exp Ther; 1997 Dec 18; 283(3):1256-63. PubMed ID: 9400001
    [Abstract] [Full Text] [Related]

  • 14. Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia.
    Langlois X, Megens A, Lavreysen H, Atack J, Cik M, te Riele P, Peeters L, Wouters R, Vermeire J, Hendrickx H, Macdonald G, De Bruyn M.
    J Pharmacol Exp Ther; 2012 Jul 18; 342(1):91-105. PubMed ID: 22490380
    [Abstract] [Full Text] [Related]

  • 15. Dopamine receptor antagonist properties of S 14506, 8-OH-DPAT, raclopride and clozapine in rodents.
    Protais P, Chagraoui A, Arbaoui J, Mocaër E.
    Eur J Pharmacol; 1994 Dec 12; 271(1):167-77. PubMed ID: 7698199
    [Abstract] [Full Text] [Related]

  • 16. Combined alpha 2-adrenergic/D2 dopamine receptor blockade fails to reproduce the ability of clozapine to reverse phencyclidine-induced deficits in prepulse inhibition of startle.
    Ballmaier M, Zoli M, Mazzoncini R, Gennarelli M, Spano F.
    Psychopharmacology (Berl); 2001 Dec 12; 159(1):105-10. PubMed ID: 11797077
    [Abstract] [Full Text] [Related]

  • 17. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms.
    Depoortère R, Auclair AL, Bardin L, Bruins Slot L, Kleven MS, Colpaert F, Vacher B, Newman-Tancredi A.
    Br J Pharmacol; 2007 May 12; 151(2):266-77. PubMed ID: 17375085
    [Abstract] [Full Text] [Related]

  • 18. Dopamine D4 receptor and anxiety: behavioural profiles of clozapine, L-745,870 and L-741,742 in the mouse plus-maze.
    Cao BJ, Rodgers RJ.
    Eur J Pharmacol; 1997 Sep 24; 335(2-3):117-25. PubMed ID: 9369363
    [Abstract] [Full Text] [Related]

  • 19. FAUC 213, a highly selective dopamine D4 receptor full antagonist, exhibits atypical antipsychotic properties in behavioural and neurochemical models of schizophrenia.
    Boeckler F, Russig H, Zhang W, Löber S, Schetz J, Hübner H, Ferger B, Gmeiner P, Feldon J.
    Psychopharmacology (Berl); 2004 Aug 24; 175(1):7-17. PubMed ID: 15007532
    [Abstract] [Full Text] [Related]

  • 20. Neuropsychopharmacological profile of remoxipride in comparison with clozapine.
    Skuza G, Rogóz Z, Wieczorek A.
    Pol J Pharmacol; 1997 Aug 24; 49(1):5-15. PubMed ID: 9431546
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.